← All trials
NCT01349192
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 1, 2011
- Primary completion
- Jan 1, 2015
- Completion date
- May 1, 2015
- First posted
- —
- Last posted
- —
- Enrollment
- 47
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- University of North Carolina at Chapel HillLead sponsor
- University of WashingtonOverall official - principal investigator
- University of North Carolina at Chapel HillOverall official - principal investigator
- University of North Carolina at Chapel HillReponsible party - principal investigator
- CF Therapeutics Development Network Coordinating CenterCollaborator
- University of WashingtonCollaborator
- University of Colorado, DenverCollaborator
- University of MichiganCollaborator
- University of FloridaCollaborator
- University of CincinnatiCollaborator
- Cook Children's Medical CenterCollaborator
- Baylor UniversityCollaborator
- University of Alabama, BirminghamCollaborator
- Washington University in St. LouisCollaborator
- The University of Texas, DallasCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.